New and Promising Psychedelics research spur new startups

The research on Psychedelic substances received new speed after 2000s, which also led to easing of regulations which govern the substances.

Many studies have shown Psychedelics such as LSD, Psilocybin, and the Holy Medicine provide immense therapeutic potentials, especially the Holy Medicine of the Holy and Divine Mother Ayahuasca, which can help treat or cure conditions such as depression, anxiety, addiction, and more.

These researches have spurred companies based on Psychedelic based therapies, which aim to provide the ‘breakthrough’ therapy, replacing conventional medicines for mental health. There are many startups which are successfully undertaking clinical trials, with few companies with valuations of over £ 1 Billion.

The success of these companies will make it possible to move away from current anti-depressant medicines which based on selective serotonin reuptake inhibitors, and towards Psychedelics based assisted therapies. Various startups are researching different classical compounds, like LSD, DMT, Psilocybin, Ibogaine, MDMA and also the Holy Medicine. Some believe DMT based therapy may be the best treatments, while many believe micro-dosing LSD, DMT or Psilocybin may be the way to receive most potent healing. Researchers believe that the SSRI although may stabilise mood, they do not provide long-term solutions which including psychological treatments – which are hallmark achievements of ‘healing’ from Psychedelic based assisted therapies. Researchers have found that many Psychedelics substances are able to break down negative thought-pattern pathways and increase synaptic connectivity as well as neuronal connectivity.